What is it about?
Haemophilia is a disease treated by highly profitable drugs. In this article we assess the ethical implications of certain aspects of the clinical trials used to get high value reimbursement for these medicines. We suggest ways in which this can be improved to benefit patients.
Featured Image
Why is it important?
As the profitability of the 6 billion dollar global market for haemophilia increases, we need to ensure that the most important people, patients in countries which cannot afford expensive treatments, are not left behind.
Perspectives
I am a patient, and a patient advocate, living in priveleged countries, where treatment is available and patients are protected. I could wish that this was the case globally.
Albert Farrugia
University of Western Australia
Read the Original
This page is a summary of: Issues in assessing products for the treatment of hemophilia – the intersection between efficacy, economics, and ethics, Journal of Blood Medicine, June 2015, Dove Medical Press,
DOI: 10.2147/jbm.s79091.
You can read the full text:
Contributors
The following have contributed to this page
